

Express Mail: EV 630723817 US
USSN: 10/749,907
Attorney Docket: I-2002.028 US C1
Response to Office Action of November 2, 2005

Amendments to the Specification

Please delete the heading “**Field of the Invention**” and its paragraph at page 2, lines 3-5.

Please insert the following heading and paragraph at page 2, immediately after the section “**Related Applications**,” and immediately before the section “**Background of the Invention**”:

Field of the Invention

The present invention is related to novel avian reoviruses that are able to grow in mammalian cells, without adaptation.

Please replace the paragraph in the section “**Related Applications**” with the following paragraph:

This application claims priority from PCT Application No. PCT/US03/031901 ~~PCTUS03/31901~~, titled “Methods of treating and preventing Neurological Symptoms Caused by Avian Reovirus and Novel Associated Characteristics,” filed October 9, [[2002]] 2003; provisional application no. 60/417,245, filed on October 9, 2002; provisional application no. 60/418,586 ~~60/418,589~~, filed on October 15, 2002, provisional application no. 60/424,163, filed on November 6, 2002; and, provisional application no. 60/435,192, filed on December 20, 2002.

Please replace the paragraph at page 15, lines 4-6 with the following paragraph:

Based upon the results comprising the study, it was determined that strains ERS 1037, ERS 060E, and ERS 074 belonged to the novel antigenic class of reoviruses identified as ERS in U.S. Patent 6,951,650 ~~application 09/493,484~~. This antigenic class of reoviruses is defined as

Express Mail: EV 630723817 US
USSN: 10/749,907
Attorney Docket: I-2002.028 US C1
Response to Office Action of November 2, 2005

having the characteristics of embodiments of the class of virus described in U.S. Patent 6,951,650. Such a class of reovirus is defined as belonging to the class of reovirus that is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by strain ERS, a sample of which is deposited at the ECACC, Salisbury, UK, under accession no. 99011475, of at least 75% in a plaque reduction assay. Such class is further defined by reactivity in an IFT with a polyclonal antiserum raised against an avian reovirus isolate, preferably against the prototype reovirus strain 1133, and the absence of reactivity in the IFT with the Moabs INT 13-06, INT 14-11 and 15-01 INT (hybridomas of which are deposited at the ECACC under accession nos. 99011472, 99011473 and 99011474, respectively). The deposited samples described in this paragraph were deposited on January 14, 1999 with the European Collection of Animal Cell Cultures (ECACC), Health Protection Agency, Centre for Applied Microbiology & Research, Porton Down, Salisbury SP4 OJG, UK.